ATF6 is Required for ANP Secretion from the Heart
ATF6 是心脏分泌 ANP 所必需的
基本信息
- 批准号:10219762
- 负责人:
- 金额:$ 34.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-12-15 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:ATF6 geneAcuteAddressAdultAffectAntioxidantsAtrial Natriuretic FactorBiological ModelsBlood PressureBlood VolumeCalciumCardiacCardiac MyocytesCardiovascular PhysiologyCardiovascular systemCell NucleusCell membraneCellsCessation of lifeChronicCleaved cellCoupledCytoplasmic GranulesDataDevelopmentDockingElementsEnsureExcretory functionFoundationsGene DeletionGene ExpressionGenesGoalsGolgi ApparatusGrowth Factor ReceptorsHeartHeart AtriumHeart failureHormone secretionHormonesHypertensionIon ChannelIschemiaLinkMammalian CellMissionModelingMorbidity - disease rateMusMuscle CellsOrganOxidative StressPathologicPathway interactionsPlasmaPlayProteinsPublic HealthQuality ControlResearchRoleRough endoplasmic reticulumRouteSNAP receptorSNAP23 geneSecretory VesiclesSiteStretchingTimeTissuesTransgenic MiceUnited States National Institutes of HealthVasodilationVentricularbasecardiovascular effectscell typedesigndietaryendoplasmic reticulum stressgain of functionhemodynamicsin vivoinnovationloss of functionmisfolded proteinmortalitymouse modelnovelnovel strategiesnovel therapeuticspeptide hormonepressureprogramsprotein foldingprotein functionprotein misfoldingsalt sensitive hypertensionsmall moleculetranscription factortranscriptome
项目摘要
Project Summary
ER protein misfolding is sensed in the rough ER by ATF6, which is expressed in all mammalian cells. We
previously showed that in ventricular myocytes, in vivo, ischemia causes ER protein misfolding, which is
sensed by ATF6, converting it to a transcription factor that induces antioxidant genes that were not known to
be ATF6-regulated in any cell type. Our objective here is to study a new role for ATF6 as a critical element in
regulated secretion, focusing on atrial natriuretic peptide (ANP), a peptide hormone made in the ER of atrial
myocytes. Neither the function of ATF6 in the atria, nor its role in regulated hormone secretion has been
studied. Therefore, this proposal addresses a novel role for ATF6 as a linchpin in regulated hormone secretion
using a cardiac model system that we call the ATF6-ANP axis. Our preliminary data showed that under non-
stressed conditions, in contrast to ventricular cell and tissue, activated ATF6 was found in atrial cell and tissue,
even in the absence of ER stress. While activated ATF6 did not increase ANP gene expression in the atria, it
was required for ANP secretion from atrial myocytes. Mechanistically, we found that ATF6 induced several
secretory pathway proteins that were not previously known to be ATF6-regulated and have not been studied in
the heart, including the SNARE protein, SNAP23. SNAP23 is known to enhance granule docking and secretion
in other cell types. Based on this background and preliminary data, our hypothesis is that ATF6 is essential
for the secretion and beneficial cardiovascular (CV) effects of ANP. SNAP23 is a mechanistic link between
ATF6 and regulated ANP secretion. We will address this hypothesis in three specific aims, which are to: 1-
examine the effects of AAV9- and small molecule-based ATF6 gain-of-function, and conditional ATF6 gene
deletion maneuvers on ANP secretion from atrial myocytes and mouse hearts, 2-determine how ATF6 gain-
and loss-of-function affects plasma ANP and hemodynamic parameters in mouse models of dietary high-salt-
induced hypertension and pressure overload-induced heart failure, and 3-define the mechanistic role of the
ATF6-inducible secretory granule docking protein, SNAP23, in ANP secretion from cultured atrial myocytes
and mouse hearts.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chris Glembotski其他文献
Chris Glembotski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chris Glembotski', 18)}}的其他基金
Non-canonical ERAD as a Regulator of Cardiac Hypertrophy
非典型 ERAD 作为心脏肥大的调节剂
- 批准号:
10544178 - 财政年份:2022
- 资助金额:
$ 34.54万 - 项目类别:
Non-canonical ERAD as a Regulator of Cardiac Hypertrophy
非典型 ERAD 作为心脏肥大的调节剂
- 批准号:
10817347 - 财政年份:2022
- 资助金额:
$ 34.54万 - 项目类别:
Non-canonical ERAD as a Regulator of Cardiac Hypertrophy
非典型 ERAD 作为心脏肥大的调节剂
- 批准号:
10363838 - 财政年份:2022
- 资助金额:
$ 34.54万 - 项目类别:
The ER Stress-Induced Selenoprotein, SelenoS, Regulates Proteostasis and Cardiac Hypertrophy
内质网应激诱导的硒蛋白 SelenoS 可调节蛋白质稳态和心脏肥大
- 批准号:
10550149 - 财政年份:2020
- 资助金额:
$ 34.54万 - 项目类别:
Harnessing the Adaptive ER Stress Response in Myocardial Ischemia
利用适应性 ER 应激反应治疗心肌缺血
- 批准号:
10227351 - 财政年份:2020
- 资助金额:
$ 34.54万 - 项目类别:
The ER Stress-Induced Selenoprotein, SelenoS, Regulates Proteostasis and Cardiac Hypertrophy
内质网应激诱导的硒蛋白 SelenoS 可调节蛋白质稳态和心脏肥大
- 批准号:
10322459 - 财政年份:2020
- 资助金额:
$ 34.54万 - 项目类别:
The ER Stress-Induced Selenoprotein, SelenoS, Regulates Proteostasis and Cardiac Hypertrophy
内质网应激诱导的硒蛋白 SelenoS 可调节蛋白质稳态和心脏肥大
- 批准号:
10218914 - 财政年份:2020
- 资助金额:
$ 34.54万 - 项目类别:
Harnessing the Adaptive ER Stress Response in Myocardial Ischemia
利用适应性 ER 应激反应治疗心肌缺血
- 批准号:
9389978 - 财政年份:2017
- 资助金额:
$ 34.54万 - 项目类别:
Harnessing the Adaptive ER Stress Response in Myocardial Ischemia
利用适应性 ER 应激反应治疗心肌缺血
- 批准号:
9924642 - 财政年份:2017
- 资助金额:
$ 34.54万 - 项目类别:
Role of the SR/ER E3 Ubiquitin Ligase Synoviolin 1 in Cardiac Hypertrophy
SR/ER E3 泛素连接酶 Synoviolin 1 在心脏肥大中的作用
- 批准号:
9102175 - 财政年份:2015
- 资助金额:
$ 34.54万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 34.54万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 34.54万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 34.54万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 34.54万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 34.54万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 34.54万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 34.54万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 34.54万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 34.54万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 34.54万 - 项目类别:
Operating Grants